UK Patients Gain Early Access to Duchenne Muscular Dystrophy Drug Through EAMS

Early Access Granted for Duchenne Muscular Dystrophy Drug

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has provided a positive scientific opinion for Santhera’s Raxone (idebenone), enabling early access to the drug for patients with Duchenne Muscular Dystrophy (DMD) through the Early Access to Medicines Scheme (EAMS). This initiative is designed to offer patients with life-threatening or seriously debilitating conditions access to unapproved treatments where there is a clear unmet medical need.

Eligibility and Safety

Patients aged 10 and above who are experiencing respiratory function decline and are not taking glucocorticoids are eligible for early access to Raxone. The MHRA's decision was based on the drug's acceptable safety profile and Santhera's ability to supply the drug at a consistent quality standard, as per company-provided information.

Regulatory Status and Future Steps

Santhera has already submitted Raxone for review by the European Medicines Agency (EMA) for the treatment of DMD, a rare inherited muscle wasting disease. In the United States, the Food and Drug Administration (FDA) has requested a second study to support existing data from the successful DELOS phase 3 study.

Industry and Patient Advocacy Response

Janet Bloor, chair of the board of trustees at Action Duchenne, expressed the critical need for new treatments in DMD and the role of the EAMS in accelerating patient access. She highlighted the organization's involvement in advising the development of the EAMS programme and welcomed the first positive opinion in DMD.

Comparative Regulatory Outcomes

While Raxone has received early access approval in the UK, PTC Therapeutics’ Translarna (ataluren) has been approved in Europe but not in the US. The EMA has granted Translarna a marketing authorisation, whereas the FDA initially refused to accept the company’s filing. PTC Therapeutics has since initiated a procedure to force a review under protest.

This development marks a significant step forward in the treatment of DMD, offering hope to patients and families affected by this devastating condition.